Dicyclomine Dosing in Children
Dicyclomine is absolutely contraindicated in infants less than 6 months of age, and for children 6 months and older, there is no FDA-approved pediatric dosing regimen established. 1
Critical Safety Contraindication
- Do not administer dicyclomine to any infant under 6 months of age under any circumstances. 1
- This is an absolute FDA contraindication due to serious safety concerns in this age group. 1
- Parents and caregivers must be explicitly counseled never to give dicyclomine to infants younger than 6 months. 1
Dosing for Children Over 6 Months
There is no established, FDA-approved dosing regimen for children older than 6 months. The FDA labeling does not provide specific pediatric dosing recommendations beyond the contraindication for infants under 6 months. 1
Historical Research Context (Not Current Recommendations)
While older research from 1984 studied dicyclomine in infants with colic, this predates the current FDA contraindication. 2 That study used dicyclomine in infants and found it eliminated colic in 63% versus 25% with placebo, but subsequent safety concerns led to the current contraindication for infants under 6 months. 2
Key Clinical Pitfalls
- Route of administration matters critically: Intravenous administration of dicyclomine can cause thrombosis and must be avoided entirely. 3
- A 2025 case report documented axillary and basilic vein thrombosis following inadvertent IV administration, likely due to M3 receptor inhibition blocking nitric oxide-mediated vasodilation. 3
- Only intramuscular or oral routes should be used if dicyclomine is prescribed for appropriate patients (not infants under 6 months). 3
Additional Contraindications Relevant to Pediatrics
Beyond age restrictions, dicyclomine is contraindicated in patients with: 1
- Unstable cardiovascular status
- Myasthenia gravis
- Glaucoma
- Obstructive uropathy
- Obstructive gastrointestinal disease
- Severe ulcerative colitis
- Reflux esophagitis